摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2-methoxy-5-trifluoromethoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine

中文名称
——
中文别名
——
英文名称
(2-methoxy-5-trifluoromethoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine
英文别名
3-(2-methoxy-5-trifluoromethoxybenzyl)-amino-2-phenylpiperidine;N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-3-amine
(2-methoxy-5-trifluoromethoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine化学式
CAS
——
化学式
C20H23F3N2O2
mdl
——
分子量
380.41
InChiKey
ZIWFCOIGUNPHPM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    27
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    42.5
  • 氢给体数:
    2
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    3-(2-Methoxy-5-trifluoromethoxybenzylamino)-2-phenylpyridine 以25.2的产率得到(2-methoxy-5-trifluoromethoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine
    参考文献:
    名称:
    [EN] PREPARATION OF SUBSTITUTED PIPERIDINES
    摘要:
    (中文)本发明公开了制备和分离式子(I)中R1和R2如下所定义的取代哌啶及其相关化合物的新工艺,以及在这些工艺中使用的新中间体。
    公开号:
    WO1993011110A1
点击查看最新优质反应信息

文献信息

  • Chemical Compounds
    申请人:Brown Alan Daniel
    公开号:US20120010182A1
    公开(公告)日:2012-01-12
    The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7 inhibitors of formula (I): or pharmaceutically acceptable salts thereof, wherein Z 1 , R a , R b , R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.
    该发明涉及磺胺衍生物,其在医学上的应用,含有它们的组合物,其制备方法以及用于这些方法的中间体。 更具体地,该发明涉及公式(I)的新磺胺基Nav1.7抑制剂: 或其药学上可接受的盐,其中Z 1 ,R a ,R b ,R 1 ,R 2 ,R 3 ,R 4 和R 5 如描述中所定义。 Nav 1.7抑制剂在治疗各种疾病,特别是疼痛方面具有潜在用途。
  • [EN] COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS<br/>[FR] COMBINAISONS CONTENANT DES LIGANDS DE ALPHA-2-DELTA
    申请人:PFIZER LTD
    公开号:WO2005092318A1
    公开(公告)日:2005-10-06
    The instant invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and an atypical antipsychotic, and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain.
    这项即时发明涉及一种组合,特别是α-2-δ配体和非典型抗精神病药物的协同组合,以及其药用盐、药物组合物及其在治疗疼痛,特别是神经病痛中的应用。
  • PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS
    申请人:Hadida Ruah Sara Sabina
    公开号:US20120196869A1
    公开(公告)日:2012-08-02
    The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    这项发明涉及对离子通道具有抑制作用的吡咯吡嘧啶-螺环哌啶酰胺化合物。该发明还提供了包括该发明化合物的药学上可接受的组合物,以及使用这些组合物治疗各种疾病的方法。
  • Benzimidazolone carboxylic acid derivatives
    申请人:Ando Koji
    公开号:US20050277671A1
    公开(公告)日:2005-12-15
    This invention relates to compounds of the formula (I): wherein R 1 , R 2 , R 3 , A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT 4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.
    这项发明涉及以下式(I)的化合物: 其中R1、R2、R3、A和m如本文所述,或其药学上可接受的盐或溶剂,以及含有这种化合物的组合物和利用这种化合物治疗由5-HT4受体活性介导的疾病的用途,例如但不限于胃食管反流病、胃肠疾病、胃动力障碍、非溃疡性消化不良、功能性消化不良、肠易激综合征(IBS)、便秘、消化不良、食管炎、胃食管疾病、恶心、中枢神经系统疾病、阿尔茨海默病、认知障碍、呕吐、偏头痛、神经系统疾病、疼痛、心血管疾病如心力衰竭和心律失常、糖尿病和呼吸暂停综合征。
  • [EN] DEUTERATED PYRIDONE AMIDES AND PRODRUGS THEREOF AS MODULATORS OF SODIUM CHANNELS<br/>[FR] AMIDES DE PYRIDONE DEUTÉRÉS ET LEURS PROMÉDICAMENTS UTILISÉS EN TANT QUE MODULATEURS DE CANAUX SODIQUES
    申请人:VERTEX PHARMA
    公开号:WO2018213426A1
    公开(公告)日:2018-11-22
    Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. The compounds have the formula (I) wherein R is H or CH2OPO(OH)2. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    提供了作为钠通道抑制剂的化合物及其药用盐。这些化合物的化学式为(I),其中R为H或CH2OPO(OH)2。还提供了包含这些化合物或药用盐的药物组合物,以及使用这些化合物、药用盐和药物组合物治疗各种疾病,包括疼痛的方法。
查看更多